1	Membrane-Localized Mutations Predict the
2	Efficacy of Cancer Immunotherapy
3	
4	Priscilla S. Briquez ¹⁺ , Sylvie Hauert ¹ *, Zoe Goldberger ^{1,2} *, Trevin Kurtanich ¹ , Aaron
5	T. Alpar ¹ , Grégoire Repond ¹ , Yue Wang ¹ , Suzana Gomes ¹ , Prabha Siddarth ³ , Melody
6	A. Swartz ^{1,4,5,6} , Jeffrey A. Hubbell ^{1,5,6+}
7	
8	* These authors contributed equally to this work
9	* Correspondence: jhubbell@uchicago.edu, pbriquez@uchicago.edu
10	
11	Affiliations:
12	¹ Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA
13	² Department of Bioengineering, McGill University, Montreal, QC, Canada
14	³ Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, CA, USA
15	⁴ Ben May Department of Cancer Research, University of Chicago, Chicago, IL, USA
16	⁵ Committee on Immunology, University of Chicago, Chicago, IL, USA
17	⁶ Committee on Cancer Biology, University of Chicago, Chicago, IL, USA

18

19 ABSTRACT

20

Due to their genetic instability, tumor cells bear mutations that can effectively 21 be recognized by the immune system. In the clinic, immune checkpoint 22 immunotherapy (ICI) can re-activate immune reactions against mutated 23 proteins, known as neoantigens, leading to remarkable remission in cancer 24 patients. Nevertheless, only a minority of patients are responsive to ICI, and 25 26 approaches for prediction of responsiveness remain elusive yet are needed to improve the success of cancer treatments. While the tumor mutational burden 27 (TMB) correlates positively with responsiveness and survival of patients 28 undergoing ICI therapy, the influence of the subcellular localizations of the 29 mutated proteins within the tumor cell has not been elucidated. Here, we 30 hypothesized that the immune reactions are modulated by the localization of 31 the mutated proteins and, therefore, that some subcellular localizations could 32 favor responsiveness to ICI. We show in both a mouse melanoma model and 33 human clinical datasets of 1722 ICI-treated patients that high membrane-34 localized tumor mutational burden (mTMB), particularly at the plasma 35 membrane, correlate with responsiveness to ICI therapy and improved overall 36 survival across multiple cancer types. We further highlight that mutations in 37 the genes encoding for the membrane proteins NOTCH3, RNF43, NTRK3 and 38 *NOTCH1*, among others, may serve as potent biomarkers to predict extended 39 survival upon ICI in certain cancer types. We anticipate that our results will 40 improve the predictability of cancer patient response to ICI and therefore may 41 have important implications to establish future clinical guidelines to direct the E: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Choice of treatment toward ICI. 42 NO 43

44 INTRODUCTION

45

Immunotherapies have revolutionized the landscape of clinical oncology, being 46 established as first-line treatments in multiple advanced cancer types, including 47 melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma¹⁻³. Despite 48 the strong efficacy of immune checkpoint immunotherapy (ICI), less than 20% of 49 patients show complete or durable response^{4,5}. While studies have shown that 50 infiltration of immune cells in the tumors⁶ and high tumor mutational burden (TMB) 51 are key correlates of response to ICI⁷⁻¹², accurate prediction of patient 52 responsiveness to ICI remains an important challenge¹³. Greater predictivity certainly 53 would increase patient survival and quality of life, by reducing the number, duration, 54 55 and side-effects of treatments as well as associated economic burden.

Here, we hypothesized that the potency of immune response against tumor mutated 56 proteins not only depends on the total mutational burden, but also on the subcellular 57 localization of these proteins within the tumor cell. Indeed, the efficiency of 58 presentation of mutated proteins on the major histocompatibility complex (MHC)-I by 59 the tumor cell, required for recognition and killing by CD8⁺ T cells¹⁴, might vary for 60 cytoplasmic, nuclear, membrane-localized or secreted proteins due to their specific 61 intracellular processing and trafficking routes¹⁵⁻¹⁷. In addition, efficiency in collection 62 63 and presentation of these mutated proteins by antigen-presenting cells (APCs), on both MHC-I and -II to generate CD8⁺ and CD4⁺ T cell responses, respectively, could 64 similarly be impacted by these different forms of proteins upon release in debris, 65 vesicles or in the extracellular milieu. Apart from antigen presentation, membrane-66 bound mutated proteins can be recognized by antibodies, induced via B cell 67 immunity, which could allow antibody-dependent cytotoxic mechanisms that kill tumor 68 cells by activating natural killer (NK) cells, macrophages or the immune complement 69 cascade^{18,19}. Of note, tumor mutated proteins that successfully activate an adaptative 70

immune response are commonly defined as tumor neoantigens.

To date, very few reports have examined how the subcellular localization of tumor 72 mutated proteins modulates anti-cancer immunity. In this study, we show that high 73 74 membrane-localized tumor mutational burden (mTMB) increase tumor immunogenicity and improve responsiveness to ICI therapies. We first demonstrated 75 76 in a mouse model of melanoma that membrane-localization of OVA (mOVA; used here as a model tumor antigen) in B16-F10 cells increased local and systemic 77 immunity as compared to soluble OVA and rendered these tumors highly susceptible 78 to ICI, in a manner that did not depend on immunoglobulin G (IgG) antibody-79 mediated cytotoxicity. We then guestioned if a high mTMB improves responsiveness 80 to ICI in cancer patients. We developed a simple algorithm that extracts the 81 subcellular localizations associated with tumor mutated genes from the 82 UniprotKB/Swiss-Prot database²⁰ and analyzed the publicly available sequencing 83 84 data of 4864 patients, treated or not with ICI, from studies by Samstein et al.⁷, Hellman et al.⁸ and Hugo et al.⁹. We demonstrated that high mTMB correlates with 85 increased patient survival and responsiveness to ICI across multiple cancer types. 86 Moreover, we highlighted that mutated genes encoding for some particular 87 membrane-localized proteins may serve as potent biomarkers to predict extended 88 survival of patients upon ICI, such as NOTCH1, NOTCH3, RNF43 or NTRK3. 89 Together, our results highlight the importance of considering the subcellular 90 localization of tumor mutated proteins, in particular mTMB, in addition to the total 91 TMB, to improve the predictivity of patient responsiveness to ICI therapy and 92 potentially the clinical guidelines for the selection of the most appropriate cancer treatment. Such findings may also have strong implications on vaccinal antigen 94 selection for neoantigen-targeted cancer vaccines based on tumor gene sequencing. 95

96

97 RESULTS

98

99 Membrane-bound antigens increase tumor immunogenicity

We began by studying the effect of cell membrane-bound antigens in the B16-F10 100 murine melanoma model. We first modified B16-F10 cells for expression of 101 membrane-bound OVA (B16mOVA), by fusing the full-length OVA sequence to the 102 transmembrane domain of H-2D^B (Fig. S1a)²¹. As a control, we used B16-F10 cells 103 that expresses full-length OVA in a soluble form (i.e., not membrane-bound; B16-104 OVA). For both designs, we generated cell lines with matching high (^{HI}) and low (^{LO}) 105 levels of OVA expression, as quantified by qPCR (Fig. S1b, c). The presence of OVA 106 at the surface of the B16mOVA cells, but not on the B16-OVA cells, was confirmed 107 by flow cytometry and fluorescence (Fig. S1d, e). We further highlighted that 108 membrane-bound OVA was secreted on extracellular vesicles produced by 109 B16mOVA (Fig. S1f), which is potentially important to increase antigen transport and 110 availability to APCs. 111

Upon intradermal injection in C57BL6 wild-type (WT) mice, all cell lines were 112 tumorigenic. We observed that B16mOVA^{HI} tumors grew significantly slower than 113 B16-OVA^{HI} and the parental B16 WT, which resulted in extended survival of mice 114 bearing B16mOVA^{HI} tumors (Fig. 1a, Fig. S1g). This effect was antigen dose-115 dependent, as seen by an intermediate growth rate of the B16mOVA^{LO} tumors. To 116 confirm that this difference was due to immune-mediated rejection of the tumor, 117 rather than to a difference in cell growth/division rate, we evaluated B16mOVA^{HI} 118 tumor growth in transgenic Act-mOVA mice, which are immune tolerant to mOVA. In 119 these mice, B16mOVA^{HI} tumors grew faster than the B16 WT tumors, demonstrating 120 an intact proliferation capacity of the B16mOVA^{HI} cells (Fig. S1h). This supports the 121 hypothesis that the slowed tumor growth in WT mice was due to an immune reaction 122 against mOVA. 123







± SEM, log-rank tests with Holm-Bonferroni p-values adjustment). f, B16mOVA^{HI} tumor 142 growth upon depletion of CD8⁺ or/and CD4⁺ T cells with anti-PD1 treatment (N≥5, mean ± 143 SEM, Kruskal-Wallis with Dunn's post-test at day 14). g, B16mOVA^{HI} tumor growth upon 144 depletion of NK1.1⁺ or/and CD8⁺ T cells with treatment with anti-PD1 (N≥5, mean ± SEM, 145 146 Kruskal-Wallis with Dunn's post-test at day 20). h, B16mOVA^{HI} tumor growth in MuMt mice (lacking mature B cells) with treatment with anti-PD-1 (N≥4, mean ± SEM, Kruskal-Wallis with 147 Dunn's post-test at day 17). i, Tumor growth of mice that survived B16mOVA^{HI} tumors treated 148 with anti-PD-1 upon rechallenge with 250k B16-F10 WT cells (N≥8, mean ± SEM, Mann-149 150 Whitney test at day 14).

151

152 Therefore, we analyzed immune cell infiltrates in the different OVA-expressing B16-F10 tumors, reasoning that increased OVA-mediated tumor rejection would enhance 153 the local presence of inflammatory cells (Fig. S2, S3). Indeed, we found a significant 154 increase of CD45⁺ immune cells in tumors that expressed mOVA as compared to 155 dose-matched soluble OVA, of about 2-fold in the case of B16mOVA^{HI} vs. B16-OVA^{HI} 156 tumors (Fig. 1b). Particularly, CD8⁺ T cells and NK cells were more numerous in this 157 tumor, but not CD4⁺ T cells (Fig. 1b, Fig. S4a-c). No difference in PD-1 expression 158 was observed on the T cells in the tumors expressing mOVA versus soluble OVA 159 (Fig. S4d). Among the other immune cell types screened, NKT cells were slightly 160 increased, and dendritic cells and B cells slightly decreased in the B16mOVA tumors 161 when quantified relative to the total CD45⁺ immune cell population (Fig. S4e). 162

Next, we assessed whether immunity against OVA in the B16mOVA-bearing mice 163 was sufficiently strong to induce systemic immunity, in addition to local intratumoral 164 inflammation. Ex vivo restimulation of splenocytes using OVA-derived MHC-I and 165 MHC-II peptides revealed that both CD8⁺ and CD4⁺ T cell responses were increased 166 in mice with tumor expressing mOVA as compared to those with soluble OVA, as 167 highlighted by the production of the pro-inflammatory cytokine interferon (IFN)-y 168 (Fig. 1c). In addition, OVA-specific antibody responses were detected in the plasma 169 of tumor-bearing mice for both B16mOVA and B16-OVA, but different subtypes of 170 immunoglobulin G (IgG) were generated, depending on the antigen localization. 171

Particularly, OVA-specific IgG2b and IgG2c were detected in mice bearing
B16mOVA tumors but were largely absent in those bearing B16-OVA tumors
(Fig. 1d, Fig. S4f).

Together, these results showed that membrane-bound tumor antigens, here modelled by mOVA, strongly enhanced tumor immunogenicity both locally and systemically, resulting in slowed tumor growth and extended survival of untreated mice.

179

180 Membrane-bound antigens restore responsiveness to ICI

While B16-F10 WT melanoma does not respond ICI, we examined whether the 181 increased immunogenicity of the B16mOVA, particularly the enhanced presence of 182 intratumoral T cells, would render them more susceptible. Remarkably, all mice 183 (5 out of 5) bearing B16mOVA^{HI} tumors and treated with anti-PD1 therapy showed 184 complete responses to ICI, whereas B16-OVA^{HI} and B16 WT-bearing mice were 185 completely unresponsive (Fig. 1e). Lowering the antigen dose in the B16mOVA^{LO} 186 group reduced the efficacy of ICI yet resulted in 2 out of 5 tumor eradications and 187 otherwise slowed tumor growth. Such effects were also confirmed using the 188 combination therapy anti-PD-L1 and anti-CTLA-4 (Fig. S4g). In both therapies, 189 responsiveness to ICI significantly extended survival. 190

We then characterized which cell types were predominantly involved in the B16mOVA^{HI} tumor rejection by depleting specific immune cells populations upon ICI treatment. In the absence of the CD4⁺ T cells, CD8⁺ T cells were still capable of controlling tumor growth and led to the rejection in 3 out of 5 mice, thus with slightly lower efficacy than with proper help from the CD4⁺ T cells, as highlighted by the isotype control group in which all tumors were rejected (Fig. 1f). In contrast, CD4⁺ T cells alone were insufficient to eradicate tumors, although they slightly slowed tumor

198 growth as compared to tumors depleted of both CD8⁺ and CD4⁺ T cells. Similarly, we 199 found that NK1.1⁺ cells were not required for responsiveness to ICI (Fig. 1g). Lastly, 200 we found that muMT⁻ transgenic mice, which lack mature B cells and cannot produce 201 IgG, were able to reject B16mOVA^{HI} tumors upon ICI, importantly highlighting that 202 IgG-based antibody-dependent cytotoxicity mechanisms were not necessary for 203 tumor eradication, although we do not exclude that they might take place in WT mice 204 (Fig. 1h).

Finally, we investigated whether the immune rejection of the B16mOVA tumors upon 205 ICI was solely directed against membrane-bound OVA or if immune reactions against 206 other tumor-associated antigens were at play. Upon re-challenge, mice that rejected 207 B16mOVA tumors showed delayed growth of B16 WT tumors, suggesting the 208 presence of pre-existing immune reactions against B16 WT neoantigens induced 209 during the initial rejection of B16mOVA (Fig. 1i, Fig. 4h). Of note, the secondary B16 210 WT tumors remained non-responsive to ICI. Therefore, while mOVA was necessary 211 to eradicate the primary tumor upon ICI, its loss in the secondary tumors still resulted 212 in delayed tumor growth, potentially mimicking a situation of cancer relapse or 213 metastasis. 214

215

216 mTMB increase patient survival upon ICI

The remarkable ability of a membrane-bound antigen (i.e., mOVA) to restore responsiveness to ICI in the murine melanoma model encouraged us to validate this hypothesis in cancer patients. Therefore, we analyzed publicly available tumor mutation sequencing data of patients treated or not with ICI, from 3 independent studies by Samstein *et al.*⁷, Hellman *et al.*⁸ and Hugo *et al.*⁹. For each tumor mutated gene detected in patients, we extracted the subcellular localization of its encoded protein from the UniProtKB/Swiss-Prot database²⁰ (Supplementary Data 1). We then

quantified per patient the number of mutated genes that encode for membrane, 224 cytoplasmic, nuclear, or secreted proteins. Genes that encode proteins expressed at 225 several localizations were classified in all locations, in a non-exclusive manner. We 226 lastly normalized the number of protein-encoding mutated genes at a specific 227 228 subcellular location to the total number of mutated genes, therefore obtaining proportions of protein-encoding mutated genes per subcellular location (Fig. 2a). 229 These proportions are here called mTMB, cTMB, nTMB or sTMB for membrane, 230 cytoplasmic, nuclear, or secreted -localized TMB, respectively. 231

We first analyzed the dataset by Samstein et al.⁷ comprising of 1609 patients with 232 233 9 different types of advanced cancers treated with ICI whose tumor mutations were determined using targeted next-generation sequencing MSK-IMPACT 234 235 (Supplementary Data 2). In total, 424 genes out of the 469 sequenced were classified in the 4 subcellular locations of interest (Fig. S5a). We compared groups of 236 patients with high and low proportion of mutated genes for each specific location 237 using the cutoff values of the upper and bottom group quartiles (Top 25% vs. Bottom 238 25%; Fig. S5b). A high mTMB was found to correlate with significantly increased 239 patient survival (Fig. 2b). This effect also was conserved at other percentiles than 240 25% (Fig. S5c). Interestingly, an insufficient mTMB was strongly associated with 241 worsened survival, as highlighted by the gradual decrease between the groups 242 Bottom 50%, 25% and 10%, with the Bottom 10% group being patients with no 243 membrane-localized mutation (Fig. 2b, Fig. S5d). None of the other subcellular 244 locations correlated with significant improvement in survival (Fig. 2c). Instead, trends 245 toward reduced survival were observed for high cTMB and nTMB, and no difference 246 was seen for sTMB. Further division into exclusive patient groups with high 247 proportions of mutated genes at a single location highlighted that the membrane 248 localization provides higher survival benefits than the cytoplasmic and nuclear 249 localizations (Fig. 2d, Fig. S5e). 250

251 Figure 2.



253 Figure 2. mTMB correlates with an increased survival in cancer patients treated with ICI in a pan-cancer analysis. Data available from Samstein et al.⁷. Patients suffering from 9 254 255 different cancer types were treated with immune checkpoint inhibitor (ICI) immunotherapy, 256 and their survival was evaluated from the first day of treatment (N=1609 patients). A control 257 cohort of patients non-treated with immunotherapy was used for comparison (N=3142 patients). All Kaplan-Meier survival curves and Cox hazard ratios (HR) for survival were 258 statistically compared using log-rank tests. a, Graphical representation of the workflow for the 259 analysis of subcellular localizations associated with the tumor mutations. b, Survival of 260 patients with high (Top 25% group) or low (Bottom 50%, 25% or 10% groups) mTMB. 261 c, Survival curves of patients having high (Top 25% group) or low (Bottom 25% group) cTMB, 262 nTMB or sTMB. d, Survival of patients as a function of their predominant subcellular location 263 of mutated genes (Top 25% groups of membrane, nucleus or cytoplasm mutations; p-values 264 265 adjusted using Holm-Bonferroni correction). e, Survival of non-ICI-treated patients that have high (Top 25%) or low (Bottom 25%) mTMB. f, HR for survival of patients having high (Top 266 25%) versus low (Bottom 25%) mTMB upon ICI treatment, non-treated with immunotherapy 267 (Non-ICI), or depending on the type of ICI received, i.e. PD-1/PDL-1, CTLA-4 or in 268 combination (HR ± 95% CI). 269

270

271 We then guestioned whether the survival advantage that correlated with high mTMB was present in non-ICI treated patients. We analyzed 3142 patients from the non-ICI 272 treated control cohort of Samstein et al.^{7,22} (Supplementary Data 3) and found that no 273 survival benefit was associated with membrane localization in absence of ICI 274 275 (Fig. 2e, f). However, all types of ICI therapies, namely PD-1/PD-L1, CTLA-4 or the combination PD-1/PD-L1 + CTLA-4, correlated with extended survival in patients 276 harboring a high mTMB, as indicated by a hazard ratio (HR) for survival inferior to 1. 277 This effect did not reach statistical significance for CTLA-4, likely due to the limited 278 279 number of patients in this group (Fig. 2f).

Together, these findings suggest that high mTMB improve cancer patient survivalupon different types of ICI treatments.

282

283 Impact of mTMB in different cancer types

284 The ICI-treated cohort analyzed above included patients with 9 different types of cancers, non-equally distributed (Fig. S6a). When comparing the distribution of 285 cancer types within the Top 25% and Bottom 25% of mTMB groups, we noticed that 286 the population with high mTMB was enriched in melanoma, renal cell carcinoma and 287 colorectal cancer patients, and depleted from bladder cancer, glioma and head-and-288 neck cancer patients (Fig. S6b). This implied that not all cancer types had the same 289 distribution of mTMB; in fact, glioma, bladder and head-and-neck cancers had 290 significantly less mTMB than the pan-cancer group, whereas colorectal and 291 melanoma cancers had significantly more (Fig. 3a). 292

293

294

295

296 Figure 3.



297

Figure 3. mTMB correlates with increased survival in multiple cancer types. 298 299 a, Distribution of mTMB by cancer types (blue line: cutoff value (CV) for the pan-cancer upper 300 quartile, red line: cutoff value for the pan-cancer lower quartile; Kruskal-Wallis test with Dunn's post-tests for comparisons to the pan-cancer group). b, Heatmap of the HR for 301 302 survival of patients harboring high versus low mutational load per subcellular location and per 303 cancer types. High and low groups are determined using either the cutoff values (CV) from 304 the pan-cancer group or the upper and lower quartiles (25%) specific to each cancer type 305 (log-rank tests).

306

Therefore, we detailed the effects of high mTMB, as well as of other subcellular 307 308 localizations, per cancer type. We computed the HR for survival to compare patients with high versus low proportions of mutated genes at a specific location, using 2 309 different strategies: 1) keeping the same cutoff values that we used for the pan-310 cancer group analysis in Fig. 2, reasoning that a "universal" threshold might be 311 312 determined across cancers as being an absolute proportion of mutations required for extended survival, or 2) using the upper and lower quartile values specific to each 313 cancer type (Fig. 3b, Fig. S6c). Overall, a high mTMB correlates with better survival 314 315 in 6 out of 9 individual cancers, with statistical significance reached in the renal cell carcinoma and head-and-neck cancer, and close to significance for esophagogastric 316 cancer. The lack of significance in the other cancer types might be due to smaller 317 effects or limited numbers of patients in each sub-cohort. On the other hand, high 318 cTMB and nTMB were associated with worsened survival in a majority of cancer 319

types (6 out of 9; 1 or 2 significantly). Besides, high sTMB did not strongly impact patient survival, except in the esophagogastric cancer, in which a trend toward improvement was observed. Interestingly, both thresholding methods for the selection of high vs. low groups showed very similar results, except for glioma and bladder cancers at the membrane locations. Further analysis with a higher number of patients would clarify whether an absolute threshold for mTMB can be determined to predict increased survival upon ICI across cancers.

327

328 mTMB predict patient response to ICI

While the metric of survival is a relevant measure to evaluate effectiveness of ICI, 329 response rate and long-term survival do not always correlate well. Hence, we searched for published datasets in which the patient response to ICI was reported. 331 332 We found 2 such studies, from Hellman et al.⁸ and Hugo et al.⁹, which respectively focused on ICI-treated patients with NSCLC (75 patients) and metastatic melanoma 333 (38 patients). Both studies used whole-exome sequencing (WES) to determine tumor 334 mutations in patients treated with anti-PD-1 or with the combination of PD-1 and 335 CTLA-4 blockade. We thus repeated the subcellular localization analysis using the 336 337 same algorithm to categories tumor mutated genes according to their possible expression in the membrane, cytoplasm, nucleus or secreted category (Fig. S7a, 338 Supplementary Data 4, 5). Because more genes were sequenced by WES than by 339 MSK-IMPACT, the detected variation range of mTMB in the WES-sequenced 340 341 patients was much smaller, with most patients having between 25-35% of mutated genes at the membrane location. Interestingly, the overall median mTMB remained 342 similar between the studies, with 33.3%, 27.0% and 34.3% in Samstein et al.7, 343 Hellman et al.⁸ and Hugo et al.⁹, respectively (Fig. S7b). The small difference of 344 lowered mTMB found in the cohort from Hellman et al.⁸ might be due to the increased 345 number of genes for which the subcellular locations could not be determined. 346

347 In this NSCLC cohort⁸, patients that responded to ICI had a significantly higher 348 mTMB, but none of the other studied locations. In addition, these patients tended to survive longer, although statistical significance was not obtained, highlighting the 349 potential discrepancy between ICI responsiveness and overall survival readouts (Fig. 350 351 4a, Fig. S7c, d). Impressively, the response rate was 61% in the group with high mTMB (25% Top), vs. 23.5% in patients with low mTMB (25% Bottom) (Fig. 4b). 352 Similar trends were also observed in the melanoma cohort, despite the low number 353 354 of patients (Fig. S7e-g). Thus, these two additional studies further support the 355 hypothesis that a high mTMB correlates with ICI responsiveness, consistently with the survival results obtained in the larger, multi-cancer cohort from Samstein et al.⁷. 356 Importantly, they also point out that this effect was conserved independently of the 357 sequencing methods used for the detection of the tumor mutations. 358

359 Figure 4.



360

361 Figure 4. mTMB correlates with better responsiveness to cancer ICI. Data available from Hellman et al.⁸. Patients (N=75) with non-small cell lung cancer were treated with a 362 363 combination of anti-PD-1 and anti-CTLA-4 immunotherapy, and their responsiveness to treatment was evaluated (responders: complete or partial response (CR/PR); non-364 responders: stable disease or progressive disease (SD/PD)). a, mTMB in patients that 365 responded or not to the immunotherapy (Mann-Whitney test). b, Proportion of responders and 366 non-responders in patients with high (Top 25%) or low (Bottom 25%) mTMB (Fisher's exact 367 368 test). c, Proportion of mutated genes at the cell plasma membrane or in other specific membrane-containing cell organelles in responders and non-responders to immunotherapy. 369 d, Heatmap of the HR for survival comparing the Top vs. Bottom 50%, 25% or 10% groups 370 having mutations at the plasma membrane or in other membrane-containing organelles, from 371 the cohorts from Samstein et al.7 (pan-cancer group), Hellman et al.8 and Hugo et al.9. 372

373 mTMB at the plasma membrane

374

375 Observing that mTMB lead to greater response to ICI, we questioned whether there were differences between particular membranes in the cell. To address this, we 376 refined our algorithm to segregate for cell membrane (i.e., plasma membrane), 377 endoplasmic reticulum, Golgi apparatus or endosome localizations. Using the data 378 on ICI responders from the NSCLC cohort⁸, we found that only the proportion of 379 mutated genes expressing proteins at the cell plasma membrane was significantly increased in ICI responders, while localization at the membranes of organelles did 381 not correlate with changes in ICI response (Fig. 4c). Similar trends were observed for 382 the melanoma cohort (Fig. S7h). In addition, consistent trends toward improvement 383 of survival for patient with increased cell plasma-localized mTMB was observed 384 across the pan-cancer, NSCLC and melanoma cohorts (Fig. 4d, Fig. S7i). 385

386

387 Membrane-localized mutations as clinical biomarkers for ICI

Finally, we analyzed which membrane protein-encoding mutated genes most impact 388 survival upon ICI. Using the dataset from Samstein et al.7, we computed the HR of 389 survival between patients bearing mutated and wild-type membrane protein-encoding 390 genes, within each cancer type (Fig. 5a, Supplementary Data 6). We observed that 391 most of the mutated genes correlated with improved survival, although a few of them 392 correlated with worsened survival. We particularly highlighted a subset of 1-13 genes 393 per cancer type for which mutations could serve as potent biomarkers to predict 394 extended survival upon ICI, as indicated by low HRs (in blue in Fig. 5a and 395 396 Supplementary Data 6). Interestingly, we found that patients bearing at least one of these biomarkers survived significantly longer than patients with none, in all the 397 cancer types for which enough patients were available, i.e., bladder cancer, 398 colorectal cancer, NSCLC, melanoma and renal cell (Fig. S8a). This represents a 399

substantial proportion of patients, between 28.4% and 74.1% depending on the
cancer type, thus highlighting a strong potential for clinical translation of these
membrane-localized biomarker sets.

Further seeking ICI-specific membrane-localized biomarkers, we compared the HRs 403 404 obtained upon ICI to the ones from the non-ICI-treated cohort, for each gene for which enough patients were available (Fig. 5a, Supplementary Data 6). In most 405 cases, gene mutations did not seem to improve survival in the non-ICI-treated cohort 406 to the same extent than in the ICI-treated cohort, suggesting that these biomarkers 407 could be specific for prediction of ICI efficacy. One exception was VHL in renal cell 408 carcinoma, for which mutations appeared to be beneficial in both cohorts. On the 409 other hand, we found that some mutated genes correlated with very high survival in 410 the ICI-treated cohort, but with worsened survival in the non-ICI-treated one, such as 411 NOTCH3 or RNF43 in colorectal cancer (the latter having been recently elucidated 412 by Zhang et al.²³), and NTRK3 and NOTCH1 in NSCLC (Fig. 5b, c, Fig. S8b, c). 413 Upon confirmation by future studies, such genes could constitute very promising 414 stand-alone biomarkers to guide medical choice toward ICI rather than other 415 treatments in specific cancer types. 416

Among the membrane-localized biomarkers that we highlighted, a few are 417 recognized by the U.S. Food and Drug Administration (FDA) as biomarkers predictive 418 of response of a FDA-approved drugs²⁴ (Fig. 5d), and thus are currently assayed in 419 the clinic. It is the case for some BRAF mutations in colorectal cancer, MET and RET 420 mutations in NSCLC, or *NTRK2/3* mutations²⁴. Therefore, we attempted to compare 421 the performance of these membrane-localized biomarkers to predict survival upon ICI 422 423 versus upon their clinically-associated treatments, using survival data from other published clinical studies by Kopetz et al.²⁵, Paik et al.²⁶ and Gautschi et al.²⁷. While 424 such direct comparisons cannot be conclusive due to intrinsic differences in the study 425 designs, BRAF and RET mutations seem highly effective as biomarkers for ICI as 426 compared to the FDA-approved encoferanib+cetuximab in colorectal cancer²⁵ 427

428 (Fig. 5e) and tepotinib in NSCLC²⁶ (Fig. 5f), respectively. A similar observation was 429 made for *RET* mutations, when compared to a standard-of-care treatment with 430 cabozantinib in NSCLC²⁷ (Fig. S8d).

Last but not least, the FDA has very recently approved the use of high TMB (i.e., 431 432 TMB \geq 10 mutations/megabase pair (mut/Mbp)) as a criterion for ICI, for adults and children with unresectable or metastatic solid tumors that failed to respond to prior 433 therapies²⁸, thus fostering the use of next-generation sequencing of tumor mutations 434 435 in the clinic. Because determination of the mTMB from these sequencing data would 436 require only a simple algorithm but no additional clinical or laboratory procedures, we examined the benefit of combining mTMB analysis with the standard total TMB 437 analysis to predict survival upon ICI. We found that a high mTMB correlated with 438 improved survival in patients with both low TMB (< 10 mut/Mbp) or high TMB 439 (≥10 mut/Mbp) (Fig. 5g, Fig. S8e, f). In addition, we observed that some patients with 440 high TMB (10-20 mut/Mbp) but low mTMB, for which ICI is approved, had similar 441 survival as patients with low TMB but high mTMB (Fig. 5h), which may not currently 442 gualify for ICI. Importantly, the latter represent 30.5% of the patients in the Samstein 443 et al. dataset, which could thus be considered for ICI but would not be otherwise. 444 Together, this suggests that the mTMB could be a valuable parameter to take into 445 account, on top of current TMB analysis, to extend the inclusion criteria for ICI in the 446 clinic. 447

Figure 5. 449



450

451 452 453

Figure 5. mTMB and specific membrane protein-encoding mutated genes as potent biomarkers for ICI in the clinic. The ICI- and non-ICI-treated cohorts from Samstein et al.⁷ were analyzed to determine which membrane protein-encoding mutated genes or 454 combination of them were the most potent to predict survival upon ICI. a, HR of survival associated with specific membrane protein-encoding genes per cancer type. A HR < 1 455 456 indicates that the mutated version of the gene correlates with increased patient survival as compared to the wild-type gene. The 1-13 membrane-associated top genes for favorable 457 458 prognosis are labelled in blue, whereas the ones for poor prognosis are in red, for the ICI-

459 treated cohort. Corresponding gene-specific HRs from the non-ICI treated cohort are in grey (log-rank test, *p < 0.05). Patient coverage indicates the proportion of patient that contains at 460 least one of the mutated genes in blue. b, Survival curves of ICI and non-ICI treated patients 461 bearing NOTCH3 mutations in colorectal cancer. c, Survival curves of ICI and non-ICI treated 462 patients bearing NTRK3 mutations in NSCLC. d, List of selected membrane protein-encoding 463 genes that are currently recognized by the FDA as biomarkers predictive of a response to 464 FDA approved drug according to the OncoKB database²⁴ (those recognized for use within the 465 same cancer type as found in Fig. 5a are shown in blue). e, Comparison of survival of 466 patients carrying BRAF mutations in colorectal cancer treated with ICI or with the FDA-467 approved encorafenib+cetuximab therapy (data from Kopetz et al.²⁵). f, Comparison of 468 469 survival of patients carrying MET mutations in NSCLC treated with ICI or with the FDAapproved tepotinib therapy (data from Paik et al.²⁶). g, Comparison of survival of patients with 470 high (> median) or low (< median) mTMB for different levels of TMB (TMB ≥ 10 mut/Mbp 471 being the FDA-validated cutoff for ICI treatment for solid tumors²⁸) in a pan-cancer analysis. 472 473 h, Survival curves comparing patients with low TMB (< 10 mut/Mbp) and high mTMB to patients with high TMB (between 10-20 mut/Mbp) and low mTMB, in a pan-cancer analysis. 474 475 No statistically significant difference was observed between the two groups (log-rank test).

- 476
- 477
- 478

479 DISCUSSION

480

This study focused on the influence of the subcellular localization of tumor mutations 481 for responsiveness to cancer immunotherapy. Importantly, we demonstrated in both 482 the B16-F10 melanoma mouse model and on a large clinical dataset of 4864 ICI- and 483 non-ICI-treated cancer patients that responsiveness to ICI and extended survival 484 correlated with a high mTMB, especially of mutations localized at the plasma 485 membrane. Interestingly, this effect was not seen for increased load of cytoplasmic, 486 nuclear, or secreted mutations, nor was it seen in patients that were not treated with 487 ICI. This conclusion was supported in a pan-cancer analysis, gathering 9 different 488 types of cancer. While pan-cancer analysis bears the limitation of merging possibly 489 490 heterogeneous cancer types, it presents the strong advantage of including a large number of patients, therefore increasing statistical power, and mirrors the design of 491 basket clinical trials currently emerging in oncology^{29,30}. Further analyses per 492

individual cancer type similarly correlated high mTMB with extended survival in renal
cell carcinoma and head and neck cancer in the cohorts from Samstein et al.⁷,
although statistical significance depended on the thresholding methods, in a
melanoma cohort from Hugo et al.⁹, and in an NSCLC cohort from Hellmann et al.⁸.
Nevertheless, in-depth analysis per cancer type would be needed on larger number
of patients to further elaborate on these conclusions, as we pointed out that high
mTMB might have varying effects in different cancer types.

500 In our analysis, we found consistent results from clinical datasets published by three independent research groups, which used two different methods of tumor mutation 501 502 sequencing, namely MSK-IMPACT and WES, both recently approved by the FDA and rapidly emerging in the clinic³¹⁻³⁴. While these sequencing methods aim to 503 504 quantify TMB, high load of which is approved as an inclusion criterion for treatment with ICI, our work provides a complementary simple algorithm-based method that 505 506 can further filter the sequencing data to improve the prediction accuracy of ICI responsiveness. We found that our mTMB criterion indicates 30.5% more patients for 507 inclusion into ICI than the current FDA standard of TMB, based on the Samstein et 508 al. dataset⁷. In addition, we highlighted particular membrane proteins-encoding 509 mutated genes that may be very potent stand-alone predictive biomarkers to guide 510 the choice toward treatment by ICI in certain cancer types. 511

Although not formally demonstrated here, the membrane-localized proteins encoded by mutated genes constituting the mTMB are likely corresponding to membranelocalized tumor neoantigens. Additional analyses of expression of the mutated genes and prediction of mutated epitope binding on patient-specific MHC molecules would be required to support this assertion. That said, both Hugo et al.⁹ and Hellmann et al.⁸ successfully demonstrated that the total TMB, particularly the amount of somatic non-synonymous single-nucleotide variants (nsSNV), strongly correlates with HLA1

neoantigen load. As to the dataset from Samstein et al., HLA subtypes of patients
were not found to be publicly available, to our knowledge, to permit such analysis.

The details of the mechanisms by which membrane-localized mutations modulate 521 522 immune responses against cancer remain to be clarified. Our data in the B16-F10 mouse model suggest that this effect strongly relies on T cells, rather than on NK 523 524 cells or on IgG-dependent cytotoxic mechanisms. While CD8⁺ T cells were necessary and sometimes sufficient to eradicate the tumors, our data supports that CD4⁺ T cells 525 provided important help to the CD8⁺ T cells, consistent with other reports that 526 stressed the key role MHC-II restricted neoantigens for responsiveness to ICI³⁵. In 527 addition, some previous research has highlighted that secreted³⁶, membrane-bound³⁷ 528 or extravesicular-bound³⁸ antigens enhance CD4⁺ T cell responses and strengthen 529 530 antigen-specific immunity, in cancer or other contexts. Considering that none of our data supported an immunogenic effect mediated by direct extracellular detection of 531 unprocessed membrane-bound antigens, such as via IgG, we did not further focus on 532 the precise effects of mutations' localization on cytoplasmic, transmembrane or 533 extracellular domain of the mutated membrane proteins in this study. Lastly, apart 534 from being immune targets, mutations of membrane proteins on tumor cells can 535 impact the primary biological functions of the proteins and their downstream 536 signaling, which could have direct effects on tumor biology, growth and 537 aggressiveness. 538

Besides the basic immunology perspective, this work provides a rationale for therapeutic immunomodulation by neoantigen selection at different subcellular locations. In particular, personalized cancer vaccines currently target neoantigens based on prediction of MHC binding neoepitopes for optimized T cell activation, with little consideration of the subcellular localization of the neoantigen¹³. Adding vaccinal antigen selection criteria for preferential targeting of plasma membrane neoantigens might improve the therapeutic efficacy of such vaccines. Taken together, we believe

546	that the simplicity of considering the neoantigens' subcellular localizations for
547	increased predictability to ICI response, the use of mTMB and specific membrane
548	neoantigens as biomarkers to guide medical decisions of cancer treatments, as well
549	as the possible impacts on the design of future immunotherapies, will be valuable in
550	the fight against cancer.

552 **REFERENCES**

553

554 1. Peters, S., Reck, M., Smit, E. F., Mok, T. & Hellmann, M. D. How to make the best use of 555 immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. 556 Annals of Oncology 30, 884–896 (2019). 557 Murciano-Goroff, Y. R., Warner, A. B. & Wolchok, J. D. The future of cancer immunotherapy: 2. 558 microenvironment- targeting combinations. Cell Research 1-13 (2020). doi:10.1038/s41422-559 020-0337-2 560 3. Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R. & Chandra, A. B. Review of Indications of 561 FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. 562 Cancers 12, 738 (2020). 563 4. Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nature 564 *Communications* **11**, 3801–3 (2020). 565 5. Robert, C. et al. Durable Complete Response After Discontinuation of Pembrolizumab in 566 Patients With Metastatic Melanoma. J Clin Oncol 36, 1668–1674 (2018). 567 6. Depil, S. Cold Tumors: A Therapeutic Challenge for Immunotherapy. 1–10 (2019). 568 doi:10.3389/fimmu.2019.00168 7. 569 Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across 570 multiple cancer types. Nat Genet 51, 202–206 (2019). 571 8. Hellmann, M. D. et al. Genomic Features of Response to Combination Immunotherapy in 572 Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33, 843-852.e4 (2018). 573 9. Hugo, W. et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in 574 Metastatic Melanoma. Cell 165, 35-44 (2016). 575 10. Keenan, T. E., Burke, K. P. & Van Allen, E. M. Genomic correlates of response to immune 576 checkpoint blockade. Nat. Med. 1-14 (2019). doi:10.1038/s41591-019-0382-x 577 11. Tran, E., Robbins, P. F. & Rosenberg, S. A. 'Final common pathway' of human cancer 578 immunotherapy: targeting random somatic mutations. Nat. Immunol. 18, 255–262 (2017). 579 12. Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D. & López-Soto, A. The hallmarks of 580 successful anticancer immunotherapy. Sci Transl Med 10, (2018). 581 13. Wells, D. K. et al. Key Parameters of Tumor Epitope Immunogenicity Revealed Through a 582 Consortium Approach Improve Neoantigen Prediction. Cell 183, 818-834.e13 (2020). 583 14. Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A. & Jaffee, E. M. Targeting neoantigens to 584 augment antitumour immunity. Nat Rev Cancer 17, 209-222 (2017). 585 15. Blum, J. S., Wearsch, P. A. & Cresswell, P. Pathways of antigen processing. Annu. Rev. 586 Immunol. 31, 443–473 (2013). 587 16. Neefjes, J., Jongsma, M. L. M., Paul, P. & Bakke, O. Towards a systems understanding of MHC 588 class I and MHC class II antigen presentation. Nat Rev Immunol 1–14 (2011). 589 doi:10.1038/nri3084 590 17. Vyas, J. M., Van der Veen, A. G. & Ploegh, H. L. The known unknowns of antigen processing 591 and presentation. Nat Rev Immunol 8, 607-618 (2008). 592 Briquez, P. S. et al. Engineering Targeting Materials for Therapeutic Cancer Vaccines. Front 18. 593 Bioeng Biotechnol 8, 19 (2020). 594 19. Almagro, J. C., Daniels-Wells, T. R., Perez-Tapia, S. M. & Penichet, M. L. Progress and 595 Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Front. 596 Immunol. 8, 495-19 (2018). 597 20. UniProt Consortium. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 598 49, D480–D489 (2021). 599 21. DiLillo, D. J., Yanaba, K. & Tedder, T. F. B cells are required for optimal CD4+ and CD8+ T cell 600 tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. The 601 Journal of Immunology **184**, 4006–4016 (2010). 602 22. Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical 603 sequencing of 10,000 patients. Nat. Med. 23, 703-713 (2017). 604 23. Zhang, N., Shi, X., Ju, W., Lou, Y. & Luo, X. Rnf43 Mutation As A Biomarker For Immune 605 Checkpoint Inhibitor Efficacy In Colorectal Cancer. (2021). doi:10.21203/rs.3.rs-536739/v1 606 24. Chakravarty, D. et al. OncoKB: A Precision Oncology Knowledge Base. JCO precision oncology

607		2017, (2017).
608	25.	Kopetz, S. <i>et al.</i> Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal
609		Cancer. N Engl J Med 381, 1632–1643 (2019).
610	26.	Paik, P. K. et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping
611		Mutations. N Engl J Med 383, 931–943 (2020).
612	27.	Gautschi, O. et al. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From
613		the Global, Multicenter RET Registry. <i>J Clin Oncol</i> 35, 1403–1410 (2017).
614	28.	U.S. Food and Drug Administration. FDA approves pembrolizumab for adults and children with
615		TMB-H solid tumors. 1–3 (2021). Available at: (Accessed: 5 July 2021)
616	29.	Lengliné, E. et al. Basket clinical trial design for targeted therapies for cancer: a French
617		National Authority for Health statement for health technology assessment. Lancet Oncol 22,
618		e430–e434 (2021).
619	30.	Subbiah, V. et al. Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma
620		Cancers. Cancer Discov 10, 657–663 (2020).
621	31.	Allegretti, M. et al. Tearing down the walls: FDA approves next generation sequencing (NGS)
622		assays for actionable cancer genomic aberrations. J. Exp. Clin. Cancer Res. 37, 47–3 (2018).
623	32.	Rusch, M. et al. Clinical cancer genomic profiling by three-platform sequencing of whole
624		genome, whole exome and transcriptome. <i>Nature Communications</i> 9 , 3962–13 (2018).
625	33.	U.S. Food and Drug Administration. U.S. FDA 510(k) clearance K190661: Omics Core
626		NantHealth. 1–182 (2019). Available at:
627		https://www.accessdata.fda.gov/cdrh_docs/reviews/K190661.pdf. (Accessed: 22nd April
628		2021)
629	34.	U.S. Food and Drug Administration. U.S. FDA 510(k) clearance K192073: Helix OpCo, LLC. 1–19
630		(2021). Available at: https://www.accessdata.fda.gov/cdrn_docs/pdf19/K192073.pdf.
631	25	(Accessed: 22nd April 2021)
632	35.	Alspach, E. <i>et al.</i> MHC-II neoantigens snape tumour immunity and response to
633	26	Immunotherapy. Nature 574 , 696–701 (2019).
034	30.	Contridy, A., Lunuin, K. O., Lorvik, K. B., Holgdard, P. O. & Bogen, B. Secretion of Tumor-Specific
636		Antigen by Myelonia Cells is Required for Cancel Infinutiosurveillance by CD4+ 1 Cells. Curicer
637	27	Henning D <i>et al.</i> The subcellular location of antigen expressed by adenoviral vectors modifies
638	57.	adaptive immunity but not dependency on cross-presenting depdritic cells. Fur, Limmunol
639		41 2185–2196 (2011)
640	38	Sedlik C <i>et al</i> Different immunogenicity but similar antitumor efficacy of two DNA vaccines
641	50.	coding for an antigen secreted in different membrane vesicle-associated forms. <i>J Extracell</i>
642		Vesicles 3. (2014)
643	39.	Mitchell, J. P., Court, J., Mason, M. D., Tabi, Z. & Clavton, A. Increased exosome production
644		from tumour cell cultures using the Integra CELLine Culture System. J. Immunol. Methods 335 .
645		98–105 (2008).
646		
5.5		

647 METHODS

648

649 OVA-expressing B16 melanoma cell lines

B16F10 (B16) melanoma cells (American Type Culture Collection, Manassas, VA, 650 USA) were genetically modified by transduction with OVA-encoding lentivirus. Briefly, 651 OVA-encoding DNA sequences were purchased from GenScript (Piscataway, NJ, 652 USA). In one design, full-length OVA (UniprotKB P01012) was fused at the N-653 terminus to the signal peptide of mouse H-2K^B (aa1-aa21, UniprotKB P01901) and at 654 the C-terminus to the transmembrane domain of mouse H-2D^B (aa299-aa331, 655 UniProtKB P01899). Sequences were subcloned in the pLV-mCherry backbone 656 (Addgene #36804) in place of mCherry. Lentiviruses were made by polyethylenimine 657 (PEI)-mediated transfection of human embryonic kidney (HEK) 293-T cells using 658 OVA-encoding plasmid with the packaging plasmids pMD2.G (Addgene #12259), 659 pMDLg/pRRE (Addgene #12251) and pRSV-Rev (Addgene #12253). Twelve hours 660 after transfection, the cell culture medium was refreshed and 36 h later, the medium 661 was collected and filtered at 0.22 µm. Lentiviruses were concentrated by 662 ultracentrifugation at 100,000 xg for 2 h at 4°C and resuspended in phosphate-663 buffered saline (PBS). B16 cells cultured in 48-well plates were transduced by adding 664 OVA-encoding lentiviruses in the culture medium and centrifuging at 1150 xg for 665 30 min at room temperature, and then were cultured for 24 h, after which the medium 666 was refreshed. For B16mOVA^{HI/LO} and B16-OVA^{HI}, monoclonal selection was 667 performed by limiting dilution, and OVA-expression was quantified by quantitative 668 polymerase chain-reaction (qPCR). The B16-OVA^{LO} cell line was a gift from B. Huard 669 (University of Geneva, Switzerland). All cell lines were tested as negative for 670 mycoplasma contamination by PCR. 671

- 672
- 673

674 Quantitative PCR for OVA expression

675 Expression of OVA in B16 cell lines or tumors was quantified by qPCR. Prior to RNA extraction, 30-50 mg of tumor tissues were homogenized (FastPrep-24 5G, MP 676 677 Biomedicals, Santa Ana, CA, USA) in RLT lysis buffer (Qiagen, Hilden, Germany), spun down at 10,000 xg for 10 min and the supernatant was collected. For cells in 678 679 culture, 1-2 million cells were pelleted, washed with PBS and lysed in RLT buffer. RNA was extracted using the RNeasy Plus Mini kit (Qiagen). The extracted RNA (1 680 µg) was then converted to cDNA using SuperScript IV VILO Master Mix 681 (ThermoFisher Scientific, Waltham, MA, USA). All kits were used according to 682 manufacturers instructions. TagMan gPCR were finally performed using TagMan 683 Universal PCR Master Mix, OVAL primer (Gg03366807 m1) and ActB primer 684 685 (Mm02619580 g1) (ThermoFisher Scientific), in a LightCycler 96 real-time PCR system (Roche Life Science, Basel, Switzerland). 686

687

688 Detection of membrane-bound OVA

Surface-expression of OVA was verified by flow cytometry and microscopy. Single 689 cell suspensions of the different OVA-expressing B16 were incubated for 30 min on 690 ice with anti-OVA (ab181688, Abcam, Cambridge, UK) in PBS + 2% fetal bovine 691 serum (FBS). Cells were washed twice and stained using an anti-rabbit secondary 692 antibody (A315723, Invitrogen, Carlsbad, CA, USA) for 20 min on ice in the dark. 693 Cells were washed and analyzed by flow cytometry (BD LSRFortessa, BD 694 Biosciences, Franklin Lakes, NJ, USA) or imaged by fluorescence microscopy (Leica 695 DMi8, Wetzlar, Germany). Flow cytometry data were analyzed using FlowJo (FlowJo 696 LLC) and microscopy images were processed using Fiji (ImageJ, U.S. National 697 698 Institutes of Health, Bethesda, MD, USA).

699

700

701 Extracellular vesicles (EV) isolation

EV from the B16mOVA^{HI} and B16-OVA^{HI} cell lines were harvested using the 702 CLAD1000 system (2440655, Cole-Parmer, Vernon Hills, IL, USA) as described by 703 Mitchell et al. ³⁹. Briefly, 16 million cells were suspended in 15 mL complete EV-704 depleted DMEM (DMEM + 1% penicillin/streptomycin (P/S) + 10% exosome-depleted 705 706 FBS (A2720801, Thermo Fisher Scientific)) and loaded into the lower chamber of the CLAD flask. The upper chamber was then loaded with DMEM + 1% P/S, and cells 707 were allowed to recover for 4 days. On the 4th day, the upper reservoir was emptied 708 and the media in the lower chamber was collected. The lower chamber was washed 709 710 twice with DMEM, collecting only the first wash. The lower chamber was then refilled with 15 mL of complete EV-depleted DMEM. This harvesting process was repeated 711 712 every 4 days. Collected media was first spun at 300 xg for 10 min to remove cells, then centrifuged at 3000 xg for 10 min to remove large cell debris and finally at 713 714 10,000 xg for 30 min to further remove debris. The final supernatant was concentrated using 100,000 MWCO concentrator tubes (UFC910024, EMD Millipore, 715 Burlington, MA, USA) before processing via size exclusion. Size exclusion was 716 performed using the Izon qEV10 system (IZON SP3) according to the manufacturer's 717 instructions to collect separately the EV fractions, containing particulates of 70-1000 718 nm in size, and the non-particulates non-EV fractions. Once purified, EV harvests 719 were pooled and re-concentrated. Total protein content of the purified EV was 720 quantified using a Micro BCA kit (Thermo Fisher) before storage at -20°C. Equal 721 amount of proteins (34 µg) were loaded on SDS-PAGE gels for further analysis by 722 western blot. 723

724

725 Western blot analysis

Samples were run on SDS-PAGE gels for 45 min at 140 V (Mini-PROTEAN gel
 system, Bio-Rad Laboratories, Hercules, CA, USA) in Laemmli loading buffer before

being transferred onto western blot membranes (Immobilon-P PVDF membrane, 728 EMD Millipore; Mini Trans-Blot cell, Bio-Rad) for 1 h at 90 V. Membranes were 729 blocked using 5% milk in PBS + 0.05% Tween-20 (PBST) overnight at 4°C under 730 agitation and probed with anti-OVA (ab181688) for 4 h at room temperature. 731 732 Membranes were washed in PBST thrice and incubated with a horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody for 1 h at room 733 temperature. Membranes were washed at least 3 times for 5 min in PBST, revealed 734 using the Clarity Western ECL substrate (Bio-Rad) and imaged using a gel imaging 735 system (Universal Hood III, Bio-Rad). 736

737

738 Mice

All animal experimentation was approved by the University of Chicago Institutional 739 740 Animal Care and Use Committee in compliance with local ethical and procedural regulations. Mice were purchased from The Jackson Laboratory (Bar Harbor, ME, 741 USA). Female C57BL/6J (No 000664) or female MuMt mice (B6.129S2-Ighm^{tm1Cgn}/J, 742 No 002288) were between 8-12 weeks old at the start of the experiments, with mice 743 being aged-matched within an experiment. Act-mOVA mice (C57BL/6-Tg(CAG-744 OVAL)916Jen/J, No 005145) were bred in-house and female mice of 25-35 week old 745 746 were used for experimentation. Mice were housed at the Animal Resources Center Facility at the University of Chicago, had water and food ad libitum, and were daily 747 monitored for health care. 748

749

750 *In vivo* antibodies

All antibodies used *in vivo* were the InVivoMAb grade antibodies purchased from Bio X Cell (Lebanon, NH, USA). Antibodies used as immune checkpoint therapies were anti-PD-1 (clone 29F.1A12), anti-PD-L1 (clone 10F.9G2) and anti-CTLA-4

(clone 9H10). Antibodies used for immune cell depletion were anti-CD8α (clone
2.43), anti-CD4 (clone GK1.5), anti-NK1.1 (clone PK136), Isotype IgG2a (clone
C1.18.4), Isotype IgG2b (clone LTF-2).

757

758 Tumor injections

Mice were anaesthetized by isoflurane inhalation and were injected intradermally with 759 1.5 million of the different OVA-expressing or WT B16 cell lines. The tumor was 760 measured using a digital caliper every 2 days, and tumor volume was calculated as 761 follows: volume = length*width*height*($\pi/6$). Mice were euthanized if sick or when the 762 763 tumor volume reached 1 cm³. When indicated, mice were treated with immunotherapy, i.e. anti-PD-1 (200 µg) or the combination anti-PDL-1 + anti-CTLA-4 764 (100 µg each), once by intraperitoneal injection when the tumor volume was between 765 20-50 mm³ (day 5-8 post-tumor injection). When needed, 500 µg of depletion 766 antibodies (anti-CD8 α , anti-CD4, anti-NK1.1 or isotype control) were injected 767 intraperitoneally 24 h after the checkpoint inhibitor therapy and repeated 7 days later. 768 In the re-challenge experiments, 250k WT B16 cells were injected intradermally on 769 the contralateral side on the mice 1 month after they cleared the primary tumor. 770

771

772 Flow cytometry analysis of tumor

Ten days after tumor injection, tumor were harvested on euthanised mice. Tumors were weighed, and about 300 mg were processed. Tumors were cut into small pieces, digested for 45 min in collagenase IV (1 mg/mL), DNAse I (40 μ g/mL) in DMEM + 2% FBS + 1.2 mM CaCl₂ at 37°C under magnetic stirring. The samples were pipetted 100 times to dissociate tumor pieces, and single cell suspensions were obtained by using 70 μ m cell strainer. Cells were kept on ice. Undigested pieces were further mixed with collagenase D (3.3 mg/mL), DNAse I (40 μ g/mL) in DMEM +

2% FBS + 1.2 mM CaCl₂ for 30 min at 37°C and collected as above. EDTA (5 mM) 780 was added to the single cell suspension. The equivalent of 20 mg of tumor was used 781 for staining for flow cytometry analysis. Tumor samples were washed in PBS and 782 stained for cell viability for 15 min using Fixable Viability Dye eFluor 455UV 783 784 (eBioscience, San Diego, CA, USA). The cells were washed and Fc receptors were blocked using anti-CD16/32 (#101302, BioLegend) for 20 min. Cells were then 785 stained for 20 min on ice using the following antibodies: anti-CD45 (30-F11), anti-786 CD8α (53-6.7), anti-PD-1 (29F.1A12), anti-NK1.1 (PK136), anti-Ly6G (1A8), anti-787 Ly6C (HK1.4), anti-CD11b (M1/70), anti-F4/80 (BM8), anti-I-A/I-E (M5/114.15.2), 788 from BioLegend (San Diego, CA, USA); anti-CD3c (145-2C11), anti-CD4 (GK1.5), 789 anti-CD62L (MEL-14), anti-CTLA-4 (UC10-4F10-11), anti-CD25 (PC61), anti-CD80 790 (16-10A1), anti-B220 (RA3-6B2), anti-CD19 (1D3), anti-CD11c (HL3), from BD 791 Biosciences; anti-CD44 (IM7), anti-CD103 (2E7), from eBioscience. Cells were 792 washed before analysis. When needed, intracellular staining with anti-FoxP3 (MF23, 793 BD Biosciences) was performed using the BD Cytofix/Cytoperm Plus kit (BD 794 Biosciences) according to the manufacturer's instruction. All staining procedures 795 were done on ice with samples protected from light, in PBS + 2% FBS + 1 mM EDTA 796 when not stated otherwise. Cells were analyzed using a LSRFortessa flow cytometer 797 (BD Biosciences). Data were processed using FlowJo (FlowJo LLC). Gating 798 strategies for the flow analysis and biomarkers used to define cell populations are 799 800 detailed in Supplementary Data 1.

801

802 Ex vivo antigen-specific T cell restimulation

Ten days after tumor injection, spleens were harvested on euthanized mice. Single cell suspensions of splenocytes were obtained using a 70 µm cell strainer. Cells were washed in PBS before the red blood cells were lysed in ACK buffer (Lonza, Basel, Switzerland) for 4 min and blocked with complete media (IMDM + 10% FBS +

807 1% P/S). Cells were centrifuged, resuspended in complete media, and 0.5 million were plated in in 96 U-bottom plate. OVA257-264 (SIINFEKL; GenScript) and OVA323-339 808 (ISQAVHAAHAEINEAGR; GenScript) were added to the splenocytes at a final 809 concentration of 1 µg/mL to restimulate CD8⁺ and CD4⁺ T cells, respectively. 810 811 Unstimulated controls were tested using complete media without peptide, and positive controls were tested using ionomycin (1 µg/mL) + PMA (50 ng/mL). After 812 4 days in culture, the cell supernatant was collected and the amount of IFNy secreted 813 814 was quantified using mouse IFNy quantikine ELISA kit (R&D systems, Minneapolis, 815 MN, USA) according to the manufacturer's instructions. Data represent the concentration of IFNy secreted in restimulated culture supernatants subtracted with 816 the amount detected in unstimulated supernatants. 817

- 818
- 819

820 IgG titration in plasma

821 Ten days after tumor injection, mice were bled by intracardiac puncture upon euthanasia. The blood was collected in EDTA-containing tubes, spun down at 822 1000 xg for 5 min and the plasma was collected and stored at -80°C until analysis. 823 824 ELISA plates (Maxisorp, Nunc, Roskilde, Denmark) were coated with 10 µg/mL OVA (Sigma-Aldrich, St. Louis, MO, USA) in PBS overnight at 4°C, and blocked with 825 casein (Sigma-Aldrich, St. Louis, MO, USA) for 2 h at room temperature. The plates 826 were washed with PBST, and plasma diluted in casein was added to the wells, 827 starting at a concentration of 1:100 and serially diluted by 10, for 2 h at room 828 temperature. The plates were washed again, and the following HRP-conjugated 829 antibodies were used for detection: anti-mouse IgG1 (#1070-05), anti-mouse IgG2a 830 (#1080-05), anti-mouse IgG2b (#1090-05) and anti-mouse IgG3 (#1100-05) from 831 Southern Biotech (Birmingham, AL, USA). The plates were revealed with TMB 832 substrate (EMD Millipore) and stopped with 2N H₂SO4. Absorbance at 450 nm was 833

read using an Epoch ELISA reader (BioTek, Winooski, VT, USA), and corrected by the absorbance at 570 nm. Antibody titers were determined as the highest plasma dilution for which the corrected absorbance was twice the background level. The area under curve (AUC) was calculated as area under the titration curve of the log₁₀(corrected absorbance over background).

839

840 Human data analysis

Processed sequencing data of tumor mutations (list of tumor mutated genes and tumor mutational burden score) and corresponding patient clinical data were obtained from the studies by Samstein *et al.*⁷, Hellman *et al.*⁸, and Hugo *et al.*⁹. Subcellular locations associated with *Homo Sapiens* genes (taxon ID = 9606) were uploaded from UniProtKB/Swiss-Prot database on August 2, 2020 and are provided in Supplementary Data 2 (Gene subcellular locations inventory). Algorithms for data processing and analysis were coded in R (Rstudio, Boston, MA, USA).

For each distinct tumor mutated gene of a patient, we searched the gene name that 848 849 matches in the gene subcellular locations inventory file. Genes that were not found were categorized as "Unfound genes". Genes that were found but for which the 850 subcellular location was unfound were further checked on the online 851 UniprotKB/Swiss-Prot database using the GetSubcellular location() function from the 852 R package 'UniprotR'. If the gene subcellular location remained unfound, it was then 853 categorized as "Unknown location". When multiple locations were found for a specific 854 gene name, they were concatenated to obtain a single subcellular location entry per 855 gene name. The gene subcellular locations were then categorized as membrane, 856 cytoplasmic, nuclear or secreted by checking the presence of the character 857 sequence: membrane = "Membrane" or "Cell membrane", cytoplasmic = 858 859 "Cytoplasm", nuclear = "Nucleus", secreted = "Secreted" in the subcellular location

entry associated with the gene. When indicated, the categories were extended to the 860 cell membrane = "Cell membrane", the endoplasmic reticulum = "Reticulum" or 861 "reticulum", the Golgi apparatus = "Golgi" or "golgi", or endosomal location = 862 "Endosome" or "endosome" or "Endosomal" or "endosomal". Oftentimes, a single 863 864 gene name was associated with several subcellular locations, in which case the gene was included in several category in an non-exclusive way. For each patient, we 865 counted the number of mutated genes at each specific subcellular locations, and the 866 proportion of mutated genes at a specific location was computed as the "number of 867 868 tumor mutated genes at a location divided by the total number of tumor mutated genes in the patient". Patients with no tumor mutated genes were removed from the 869 analysis. In the presented data, groups of patients were determined using inclusive 870 percentiles, except in groups separated at the median, for which the group below 871 median was inclusive and the group above median was exclusive. In Fig. 5, "mTMB 872 High" and "mTMB Low" correspond to groups of patients for which mTMB was 873 874 respectively higher and lower than the median.

In R, survival analysis were performed using the libraries 'survival', 'survminer' and 'survcomp' and the functions survfit() and surv_pvalue(). Hazard ratios were computed using the function hazard.ratio(). All these functions were used using logrank tests when asked. In case of multiple comparisons, p-values were adjusted using the function p.adjust().

880

881 Analysis of the membrane-localized biomarkers

HR of survival was computed for each membrane protein-encoding gene, between
patients that bear mutated version of the gene vs. patients that bear the wild-type
version of the gene. The analysis was done independently for each cancer type.
Results were considered relevant to report (in Fig. 5) when at least 7 patients with a

mutated version of a gene were available, and 1) when the HR was ≤ 0.5 or statistically significance by the log-rank test was reached, or 2) when the HR ratio was ≥ 1.3 and close to statistically significance (p-value < 0.2). The non ICI-treated cohort results were reported when at least 7 patients had the mutated version of the gene of interest.

891

892 Statistics & Software

Graphs were plotted using Prism 9 (GraphPad, San Diego, CA, USA). Statistical
analysis were run on Prism 9 or on R (RStudio). Overall threshold for statistical
significance was considered as p-value < 0.05. Figures were made on Illustrator CS5
(Adobe, San Jose, CA, USA).

897

898 Material, data and code availability

Tumor mutation sequencing data for the human cohorts used in this study are publicly available from Samstein *et al.*⁷, Hellman *et al.*⁸ and Hugo *et al.*⁹. Subcellular locations associated to *Homo Sapiens* genes are provided in Supplementary Data 1 and updated versions can be downloaded from the UniProtKB/Swiss-Prot database. Proportion of mutation subcellular locations per patient and corresponding selected clinical data are provided in Supplementary Data 2-5. Other material, data and code remains available upon request to the corresponding authors.

- 906
- 907
- 908
- 909

910

911

912 SUPPLEMENTARY INFORMATION

- 913
- Supplementary Data 1: Subcellular locations of proteins associated with Homo
 Sapiens genes.
- Supplementary Data 2: Proportion of mutations at specific location for ICI-treated
 cohort from Samstein *et al.*⁷
- 918 **Supplementary Data 3:** Proportion of mutations at specific location for the non-ICI-
- 919 treated cohort from Samstein *et al.*⁷
- 920 Supplementary Data 4: Proportion of mutations at specific location for the NSCLC
- 921 patients cohort from Hellman et al.8
- 922 **Supplementary Data 5:** Proportion of mutations at specific location for the 923 melanoma patients cohort from Hugo *et al.*⁹
- Supplementary Data 6: HR of survival per mutated genes and per cancer type for
 the ICI and non-ICI treated patients cohort from Samstein *et al.*⁷
- 926

927

928 ACKNOWLEDGMENTS

929

The authors would like to thank Prof. Luc G. T. Morris and Prof. David B. Solit for their help in the use of their clinical dataset, Dr. Raga Krishnakumar, Dr. Alexandre de Titta and Dr. Sandra Gribi for advice on data analysis and Dr. Jialu Liu for technical assistance. This article is dedicated to the memory of Anthony Gomes. This work was funded by the Chicago Immunoengineering Innovation Center of the University of Chicago and NIH R01 CA219304 (to M.A.S.).

936

937	
938	AUTHOR CONTRIBUTIONS
939	
940	P.S.B., S.H., M.A.S. and J.A.H. have conceived the project and designed the
941	experiments. P.S.B., S.H., Z.G., T.K., A.T.A., G.R., Y.W. and S.G., performed the
942	experiments. P.S.B., S.H., Z.G., T.K, P.B and J.A.H. analyzed and interpreted the
943	data. P.S.B, J.A.H., and Z.G. wrote the manuscript, and S.H., P.B. and M.A.S.
944	corrected it.
945	
946	
947	COMPETING INTERESTS
948	
949	The University of Chicago has filed for patent protection for biomarkers described in
950	this work, upon which P.S.B., Z.G., S.H. and J.A.H. are inventors. Other authors
951	have no competing interest to declare.
952	